ARCHIVED: Everolimus improves progression-free survival for patients with advanced, nonfunctional neuroendocrine tumors of the lung, gastrointestinal tract
MD Anderson led research in field, from small investigator-initiated studies to international confirmatory trials
MD Anderson News Release 09/26/2015
In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has shown to dramatically improve progression-free survival for patients with advanced, nonfunctional neuroendocrine tumors (NET) of the lung and gastrointestinal...
ARCHIVED: Breakthrough study demonstrates survival advantage with immune checkpoint inhibitor for advanced kidney cancer patients
CheckMate-025 study led by The University of Texas MD Anderson Cancer Center portends paradigm change in standard of care treatment...
ARCHIVED: MD Anderson study identifies leukemia tumor suppressor
Protein-coding gene hnRNP K may be culprit in acute myeloid leukemia
MD Anderson News Release 09/24/2015
A protein-coding...
ARCHIVED: A Conversation With a Living Legend® returns to San Antonio to honor Emmitt Smith
Football legend teams up with MD Anderson to support cancer research
MD Anderson News Release 09/22/2015
The University of Texas MD Anderson Cancer Center heads to San Antonio Oct. 13 for the sixth annual A Conversation With a Living Legend® honoring Pro Football Hall of Fame member and “Dancing with the Stars” champion Emmitt Smith.
The luncheon and program will be held at the Marriott Rivercenter, 101...
ARCHIVED: MD Anderson, Cayman Chemical, and Fannin Innovation Studio form therapeutics company
ACF Pharmaceuticals to explore the potential of novel, small molecule anti-cancer agents
MD Anderson News Release 09/15/2015
...
ARCHIVED: MD Anderson immunologist Jim Allison wins Lasker-DeBakey Award
Cancer immunotherapy pioneer awarded prestigious U.S. medical research honor
MD Anderson News Release 09/08/2015
For inventing...
ARCHIVED: MD Anderson and Cellectis announce pre-clinical and clinical alliance in cancer immunotherapy
MD Anderson News Release 09/03/2015
Cellectis, the gene editing company employing proprietary technologies to develop best-in-class...
ARCHIVED: MD Anderson brings Making Cancer History® seminar to Atlanta
Free event offers information on the latest cancer treatment and prevention strategies
MD Anderson News Release 09/03/2015...
ARCHIVED: MD Anderson to honor Houstonians for their efforts to end cancer
River Oaks Country Club event to pay tribute to Houston community
MD Anderson News Release 09/02/2015
The University...
ARCHIVED: Michelle Barton receives Rogers Award for Excellence in Education
Esteemed educator strives to ‘put the students first’
MD Anderson News Release 09/01/2015
Michelle Barton, Ph.D., professor...